Ostin Technology Group Key Executives
This section highlights Ostin Technology Group 's key executives, including their titles and compensation details.
Find Contacts at Ostin Technology Group
(Showing 0 of )
Ostin Technology Group Earnings
This section highlights Ostin Technology Group 's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Ostin Technology Group , including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $32.46M | $57.53M | $105.42M | $167.74M | $140.07M |
| Cost of Revenue | $30.78M | $55.47M | $92.80M | $150.39M | $128.20M |
| Gross Profit | $1.69M | $2.05M | $12.61M | $17.36M | $11.87M |
| Gross Profit Ratio | 5.19% | 3.57% | 11.96% | 10.35% | 8.47% |
| Research and Development Expenses | $1.70M | $2.78M | $2.52M | $5.71M | $2.83M |
| General and Administrative Expenses | $7.57M | $7.34M | $7.65M | $4.99M | $2.74M |
| Selling and Marketing Expenses | $2.05M | $2.39M | $2.79M | $3.97M | $2.17M |
| Selling General and Administrative Expenses | $9.62M | $9.72M | $10.44M | $8.96M | $4.91M |
| Other Expenses | $-101.18K | $-194.53K | $-1.51M | $-517.05K | $-741.23K |
| Operating Expenses | $11.22M | $12.31M | $11.45M | $14.15M | $7.74M |
| Cost and Expenses | $41.99M | $67.78M | $104.26M | $164.54M | $135.94M |
| Interest Income | $- | $- | $1.29M | $1.11M | $688.40K |
| Interest Expense | $- | $1.27M | $1.29M | $1.11M | $688.40K |
| Depreciation and Amortization | $4.78M | $3.20M | $2.58M | $2.16M | $1.41M |
| EBITDA | $-4.20M | $-6.47M | $3.02M | $6.85M | $4.56M |
| EBITDA Ratio | -12.94% | -11.25% | 2.87% | 4.09% | 3.26% |
| Operating Income | $-9.53M | $-10.26M | $450.42K | $3.22M | $4.13M |
| Operating Income Ratio | -29.35% | -17.83% | 0.43% | 1.92% | 2.95% |
| Total Other Income Expenses Net | $-636.93K | $-530.74K | $-11.25K | $21.06K | $-755.77K |
| Income Before Tax | $-10.17M | $-10.79M | $439.17K | $3.24M | $2.70M |
| Income Before Tax Ratio | -31.32% | -18.75% | 0.42% | 1.93% | 1.93% |
| Income Tax Expense | $23.15K | $227.32K | $326.94K | $-57.09K | $-126.72K |
| Net Income | $-10.06M | $-10.95M | $112.23K | $3.10M | $2.71M |
| Net Income Ratio | -30.99% | -19.03% | 0.11% | 1.85% | 1.94% |
| EPS | $-6.74 | $-7.82 | $0.01 | $0.23 | $0.20 |
| EPS Diluted | $-6.74 | $-0.78 | $0.01 | $0.23 | $0.20 |
| Weighted Average Shares Outstanding | 1.49M | 1.40M | 11.77M | 13.50M | 13.50M |
| Weighted Average Shares Outstanding Diluted | 1.49M | 14.01M | 11.77M | 13.50M | 13.50M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.75M | $8.75M | $7.49M | $7.49M | $23.23M | $11.62M | $34.30M | $17.15M | $45.32M | $22.66M | $60.09M | $30.05M | $80.37M | $40.19M | $87.37M | $43.69M | $83.86M | $41.93M | $56.21M | $28.11M |
| Cost of Revenue | $8.35M | $8.35M | $7.04M | $7.04M | $21.87M | $10.93M | $33.60M | $16.80M | $41.34M | $20.67M | $51.46M | $25.73M | $72.83M | $36.57M | $77.54M | $38.77M | $77.28M | $38.78M | $50.92M | $25.46M |
| Gross Profit | $397.95K | $397.95K | $445.19K | $445.19K | $1.36M | $680.81K | $691.99K | $345.99K | $3.98M | $1.99M | $8.63M | $4.32M | $7.55M | $3.61M | $9.83M | $4.92M | $6.58M | $3.15M | $5.29M | $2.65M |
| Gross Profit Ratio | 4.55% | 4.55% | 5.95% | 5.95% | 5.86% | 5.86% | 2.02% | 2.02% | 8.78% | 8.78% | 14.37% | 14.37% | 9.39% | 8.99% | 11.25% | 11.25% | 7.84% | 7.50% | 9.42% | 9.42% |
| Research and Development Expenses | $367.71K | $367.71K | $482.58K | $482.58K | $1.35M | $676.30K | $1.43M | $715.20K | $487.20K | $243.60K | $2.03M | $1.01M | $2.71M | $1.36M | $3.00M | $1.50M | $1.62M | $808.65K | $1.21M | $605.71K |
| General and Administrative Expenses | $2.33M | $2.33M | $1.45M | $1.45M | $2.08M | $2.08M | $1.59M | $1.59M | $2.05M | $2.05M | $1.78M | $1.78M | $1.73M | $1.15M | $1.06M | $1.06M | $963.76K | $963.76K | $597.85K | $597.85K |
| Selling and Marketing Expenses | $574.75K | $574.75K | $448.53K | $448.53K | $529.87K | $529.87K | $662.96K | $662.96K | $686.77K | $686.77K | $709.83K | $709.83K | $778.82K | $778.82K | $1.20M | $1.20M | $610.25K | $610.25K | $475.95K | $475.95K |
| Selling General and Administrative Expenses | $2.91M | $2.91M | $1.90M | $1.90M | $5.22M | $2.61M | $4.50M | $2.25M | $5.47M | $2.74M | $4.97M | $2.49M | $3.68M | $1.93M | $4.52M | $2.26M | $2.76M | $1.57M | $2.15M | $1.07M |
| Other Expenses | $-10.07K | $-10.07K | $-40.52K | $-40.52K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $3.27M | $3.27M | $2.34M | $2.34M | $6.57M | $3.15M | $5.93M | $2.64M | $5.96M | $2.25M | $7.00M | $3.19M | $6.39M | $2.52M | $7.52M | $3.84M | $4.38M | $2.18M | $3.36M | $1.91M |
| Cost and Expenses | $11.61M | $11.61M | $9.38M | $9.38M | $28.44M | $14.08M | $39.54M | $19.44M | $47.30M | $22.92M | $58.46M | $28.92M | $79.22M | $39.09M | $85.06M | $42.61M | $81.66M | $40.97M | $54.28M | $27.37M |
| Interest Income | $- | $- | $- | $- | $364.04K | $364.04K | $272.46K | $272.46K | $274.57K | $274.57K | $370.83K | $370.83K | $327.77K | $327.77K | $228.26K | $228.26K | $167.36K | $167.36K | $176.84K | $176.84K |
| Interest Expense | $- | $- | $1.10M | $- | $728.09K | $- | $544.92K | $- | $549.14K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $1.29M | $1.29M | $618.68K | $618.68K | $1.68M | $653.00K | $1.44M | $611.36K | $1.35M | $657.08K | $1.23M | $537.01K | $1.12M | $509.48K | $1.04M | $517.66K | $689.49K | $309.17K | $718.82K | $240.39K |
| EBITDA | $-1.59M | $-1.59M | $-1.32M | $-1.32M | $-3.26M | $-1.95M | $-3.14M | $-2.01M | $831.79K | $-333.35K | $3.48M | $1.35M | $3.31M | $839.80K | $3.19M | $1.67M | $2.61M | $1.07M | $2.19M | $1.21M |
| EBITDA Ratio | -18.15% | -18.15% | -17.60% | -17.60% | -14.02% | -16.81% | -9.17% | -11.71% | 1.84% | -1.47% | 5.78% | 4.51% | 4.12% | 2.09% | 3.66% | 3.83% | 3.12% | 2.56% | 3.89% | 4.30% |
| Operating Income | $-2.87M | $-2.87M | $-1.90M | $-1.90M | $-5.21M | $-2.61M | $-5.24M | $-2.62M | $-1.98M | $-990.43K | $1.64M | $817.75K | $1.15M | $330.32K | $2.31M | $1.16M | $2.20M | $762.67K | $1.93M | $967.49K |
| Operating Income Ratio | -32.80% | -32.80% | -25.32% | -25.32% | -22.43% | -22.43% | -15.28% | -15.28% | -4.37% | -4.37% | 2.72% | 2.72% | 1.43% | 0.82% | 2.64% | 2.64% | 2.62% | 1.82% | 3.44% | 3.44% |
| Total Other Income Expenses Net | $110.33K | $110.33K | $-428.80K | $-428.80K | $-451.56K | $-225.78K | $115.34K | $-22.47K | $-276.19K | $196.26K | $-127.33K | $-201.89K | $382.76K | $221.93K | $-607.64K | $-303.82K | $-609.57K | $32.15K | $-820.06K | $-410.03K |
| Income Before Tax | $-2.76M | $-2.76M | $-2.32M | $-2.32M | $-5.66M | $-2.83M | $-5.12M | $-2.56M | $-1.07M | $-534.50K | $1.51M | $754.09K | $1.54M | $767.64K | $1.70M | $851.57K | $1.59M | $794.82K | $1.11M | $557.46K |
| Income Before Tax Ratio | -31.54% | -31.54% | -31.05% | -31.05% | -24.37% | -24.37% | -14.94% | -14.94% | -2.36% | -2.36% | 2.51% | 2.51% | 1.91% | 1.91% | 1.95% | 1.95% | 1.90% | 1.90% | 1.98% | 1.98% |
| Income Tax Expense | $11.58K | $11.58K | $- | $-44.60K | $335.51K | $167.76K | $-108.19K | $54.09K | $20.43K | $10.21K | $306.51K | $153.26K | $-306.15K | $153.08K | $249.06K | $124.53K | $-333.77K | $166.89K | $207.05K | $103.52K |
| Net Income | $-2.71M | $-2.71M | $-2.32M | $-2.32M | $-5.96M | $-2.98M | $-4.99M | $-2.49M | $-1.00M | $-500.46K | $1.20M | $599.95K | $1.67M | $834.39K | $1.43M | $715.08K | $1.79M | $894.70K | $924.71K | $462.35K |
| Net Income Ratio | -30.99% | -30.99% | -31.00% | -31.00% | -25.65% | -25.65% | -14.55% | -14.55% | -2.21% | -2.21% | 2.00% | 2.00% | 2.08% | 2.08% | 1.64% | 1.64% | 2.13% | 2.13% | 1.64% | 1.64% |
| EPS | $-1.93 | $-1.93 | $-0.15 | $-0.15 | $-0.43 | $-0.21 | $-0.36 | $-0.18 | $-0.07 | $-0.04 | $0.09 | $0.06 | $0.12 | $0.08 | $0.11 | $0.07 | $0.13 | $0.09 | $0.07 | $0.05 |
| EPS Diluted | $-1.93 | $-1.93 | $-0.15 | $-0.15 | $-0.43 | $-0.21 | $-0.36 | $-0.18 | $-0.07 | $-0.04 | $0.09 | $0.06 | $0.12 | $0.08 | $0.11 | $0.07 | $0.13 | $0.09 | $0.07 | $0.05 |
| Weighted Average Shares Outstanding | 1.40M | 1.40M | 15.84M | 15.84M | 14.01M | 14.01M | 14.01M | 14.01M | 14.01M | 13.42M | 13.50M | 10.13M | 13.50M | 10.13M | 13.50M | 10.13M | 13.50M | 10.13M | 13.50M | 10.13M |
| Weighted Average Shares Outstanding Diluted | 1.40M | 1.40M | 15.84M | 15.84M | 14.01M | 14.01M | 14.01M | 14.01M | 14.01M | 13.42M | 13.50M | 10.12M | 13.50M | 10.12M | 13.50M | 10.12M | 13.50M | 10.12M | 13.50M | 10.12M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.02M | $854.52K | $3.66M | $684.34K | $5.34M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.02M | $854.52K | $3.66M | $684.34K | $5.34M |
| Net Receivables | $5.96M | $7.13M | $6.36M | $25.65M | $12.90M |
| Inventory | $11.11M | $15.93M | $15.43M | $18.69M | $17.95M |
| Other Current Assets | $2.75M | $523.25K | $6.46M | $7.74M | $9.10M |
| Total Current Assets | $20.84M | $24.44M | $31.91M | $54.19M | $45.29M |
| Property Plant Equipment Net | $24.52M | $25.20M | $19.42M | $19.47M | $14.95M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $5.71M | $6.46M | $4.25M | $1.62M | $1.81M |
| Goodwill and Intangible Assets | $5.71M | $6.46M | $4.25M | $1.62M | $1.81M |
| Long Term Investments | $- | $205.59K | $210.87K | $-1.50M | $-1.50M |
| Tax Assets | $- | $- | $566.40K | $673.18K | $882.01K |
| Other Non-Current Assets | $- | $248.01K | $823.12K | $1.50M | $1.50M |
| Total Non-Current Assets | $30.23M | $32.11M | $25.28M | $21.77M | $17.64M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $51.07M | $56.55M | $57.18M | $75.97M | $62.93M |
| Account Payables | $6.34M | $10.80M | $6.28M | $17.62M | $23.24M |
| Short Term Debt | $26.17M | $27.03M | $22.01M | $35.81M | $15.19M |
| Tax Payables | $48.72K | $54.17K | $250.72K | $- | $- |
| Deferred Revenue | $1.03M | $648.36K | $2.41M | $4.51M | $5.76M |
| Other Current Liabilities | $7.37M | $2.01M | $3.01M | $7.14M | $12.54M |
| Total Current Liabilities | $40.96M | $40.53M | $31.51M | $60.57M | $51.37M |
| Long Term Debt | $1.71M | $1.66M | $- | $199.60K | $700.60K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $516.94K | $271.59K | $52.59K | $- | $- |
| Total Non-Current Liabilities | $2.23M | $1.93M | $52.59K | $199.60K | $295.01K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $43.19M | $42.46M | $31.56M | $60.76M | $51.67M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.77K | $1.40K | $1.40K | $1.01K | $1.01K |
| Retained Earnings | $-18.53M | $-8.47M | $2.48M | $2.75M | $19.00K |
| Accumulated Other Comprehensive Income Loss | $-742.91K | $-833.84K | $-405.79K | $717.64K | $98.10K |
| Other Total Stockholders Equity | $24.46M | $23.26M | $23.26M | $10.86M | $10.49M |
| Total Stockholders Equity | $5.19M | $13.96M | $25.34M | $14.32M | $10.60M |
| Total Equity | $7.89M | $14.09M | $25.63M | $15.20M | $11.26M |
| Total Liabilities and Stockholders Equity | $51.07M | $56.55M | $57.18M | $75.97M | $62.93M |
| Minority Interest | $2.69M | $130.22K | $289.00K | $878.97K | $659.47K |
| Total Liabilities and Total Equity | $51.07M | $56.55M | $57.18M | $75.97M | $62.93M |
| Total Investments | $- | $205.59K | $210.87K | $-1.50M | $-1.50M |
| Total Debt | $27.88M | $25.68M | $21.53M | $32.81M | $15.43M |
| Net Debt | $26.85M | $24.82M | $17.88M | $32.13M | $10.09M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.02M | $1.02M | $1.74M | $1.74M | $854.52K | $854.52K | $2.62M | $2.62M | $3.66M | $3.66M | $3.53M | $3.53M | $684.34K | $684.34K | $2.14M | $2.14M | $5.34M | $5.34M | $2.79M | $2.78M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.02M | $1.02M | $1.74M | $1.74M | $854.52K | $854.52K | $2.62M | $2.62M | $3.66M | $3.66M | $3.53M | $3.53M | $684.34K | $684.34K | $2.14M | $2.14M | $5.34M | $5.34M | $2.79M | $2.78M |
| Net Receivables | $5.96M | $3.92M | $4.81M | $4.81M | $6.48M | $6.48M | $4.65M | $4.65M | $6.36M | $6.27M | $16.02M | $15.57M | $25.65M | $25.65M | $15.58M | $14.75M | $12.90M | $11.91M | $8.34M | $8.34M |
| Inventory | $11.11M | $13.55M | $12.99M | $12.99M | $14.42M | $15.93M | $16.19M | $19.32M | $15.43M | $21.53M | $20.13M | $23.72M | $18.69M | $25.99M | $15.97M | $29.83M | $17.95M | $26.50M | $17.67M | $17.67M |
| Other Current Assets | $2.75M | $2.36M | $770.72K | $1.45M | $2.46M | $1.17M | $4.22M | $1.71M | $6.46M | $451.31K | $5.61M | $2.47M | $7.74M | $1.87M | $14.99M | $1.95M | $9.10M | $1.54M | $1.26M | $1.27M |
| Total Current Assets | $20.84M | $20.84M | $21.00M | $21.00M | $24.44M | $24.44M | $28.30M | $28.30M | $31.91M | $31.91M | $45.29M | $45.29M | $54.19M | $54.19M | $48.68M | $48.68M | $45.29M | $45.29M | $30.06M | $30.06M |
| Property Plant Equipment Net | $24.52M | $24.52M | $23.82M | $23.82M | $25.20M | $25.20M | $23.44M | $23.44M | $19.42M | $19.42M | $20.11M | $20.11M | $19.47M | $19.47M | $17.56M | $17.56M | $14.95M | $14.95M | $12.23M | $12.23M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $5.71M | $5.71M | $6.15M | $6.15M | $6.46M | $6.46M | $4.41M | $4.41M | $4.25M | $4.25M | $1.57M | $1.57M | $1.62M | $1.62M | $1.71M | $1.71M | $1.81M | $1.81M | $398.63K | $398.63K |
| Goodwill and Intangible Assets | $5.71M | $5.71M | $6.15M | $6.15M | $6.46M | $6.46M | $4.41M | $4.41M | $4.25M | $4.25M | $1.57M | $1.57M | $1.62M | $1.62M | $1.71M | $1.71M | $1.81M | $1.81M | $398.63K | $398.63K |
| Long Term Investments | $- | $- | $207.75K | $207.75K | $205.59K | $205.59K | $218.42K | $218.42K | $210.87K | $210.87K | $-535.88K | $- | $-1.50M | $- | $-841.65K | $- | $-1.50M | $- | $-672.91K | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $558.87K | $- | $566.40K | $- | $535.88K | $- | $673.18K | $- | $841.65K | $- | $882.01K | $- | $672.91K | $- |
| Other Non-Current Assets | $- | $- | $267.82K | $267.82K | $248.01K | $248.01K | $744.47K | $1.30M | $823.12K | $1.44M | $535.88K | $535.88K | $1.50M | $673.18K | $841.65K | $841.65K | $1.50M | $882.01K | $672.91K | $672.91K |
| Total Non-Current Assets | $30.23M | $30.23M | $30.44M | $30.44M | $32.11M | $32.11M | $29.38M | $29.38M | $25.28M | $25.33M | $22.21M | $22.21M | $21.77M | $21.77M | $20.11M | $20.11M | $17.64M | $17.64M | $13.31M | $13.31M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- |
| Total Assets | $51.07M | $51.07M | $51.44M | $51.44M | $56.55M | $56.55M | $57.68M | $57.68M | $57.18M | $57.23M | $67.51M | $67.51M | $75.97M | $75.97M | $68.79M | $68.79M | $62.93M | $62.93M | $43.37M | $43.37M |
| Account Payables | $6.34M | $6.34M | $5.31M | $5.31M | $10.80M | $10.80M | $6.96M | $6.96M | $6.28M | $6.28M | $11.52M | $11.52M | $17.62M | $17.62M | $21.41M | $21.41M | $23.24M | $23.24M | $14.23M | $14.23M |
| Short Term Debt | $26.17M | $30.95M | $26.86M | $30.83M | $27.03M | $27.03M | $26.97M | $26.97M | $21.28M | $22.01M | $31.69M | $33.02M | $35.81M | $35.81M | $16.52M | $17.83M | $15.19M | $16.10M | $15.46M | $15.46M |
| Tax Payables | $48.72K | $- | $15.56K | $- | $54.17K | $- | $39.14K | $- | $250.72K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $310.92K | $- |
| Deferred Revenue | $1.03M | $- | $339.34K | $223.26K | $1.56M | $- | $2.69M | $- | $2.41M | $- | $3.54M | $- | $4.51M | $- | $6.53M | $- | $5.76M | $- | $1.19M | $- |
| Other Current Liabilities | $7.37M | $3.67M | $6.24M | $2.91M | $2.65M | $2.71M | $3.18M | $3.22M | $2.28M | $3.26M | $5.35M | $6.24M | $7.14M | $7.14M | $11.92M | $15.83M | $12.54M | $11.63M | $4.10M | $4.41M |
| Total Current Liabilities | $40.96M | $40.96M | $39.05M | $39.05M | $40.53M | $40.53M | $37.15M | $37.15M | $31.51M | $31.56M | $50.78M | $50.78M | $60.57M | $60.57M | $55.08M | $55.08M | $51.37M | $50.97M | $34.10M | $34.10M |
| Long Term Debt | $1.71M | $1.71M | $- | $- | $1.66M | $1.66M | $291.22K | $291.22K | $- | $- | $45.36K | $45.36K | $199.60K | $199.60K | $385.25K | $385.25K | $700.60K | $700.60K | $295.35K | $295.35K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $516.94K | $516.94K | $725.17K | $725.17K | $271.59K | $271.59K | $47.28K | $47.28K | $52.59K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $2.23M | $2.23M | $725.17K | $725.17K | $1.93M | $1.93M | $338.50K | $338.50K | $52.59K | $- | $45.36K | $45.36K | $199.60K | $199.60K | $385.25K | $385.25K | $295.01K | $700.60K | $295.35K | $295.35K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $43.19M | $43.19M | $39.78M | $39.78M | $42.46M | $42.46M | $37.49M | $37.49M | $31.56M | $31.56M | $50.82M | $50.82M | $60.76M | $60.76M | $55.46M | $55.46M | $51.67M | $51.67M | $34.40M | $34.40M |
| Preferred Stock | $- | $- | $- | $24.24M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.77K | $1.77K | $1.68K | $1.68K | $1.40K | $1.40K | $1.40K | $1.40K | $1.40K | $1.40K | $1.01K | $1.01K | $1.01K | $1.01K | $1.01K | $1.01K | $1.01K | $1.01K | $3.73K | $3.73K |
| Retained Earnings | $-18.53M | $-17.03M | $-13.11M | $-11.61M | $-8.47M | $-6.97M | $-2.51M | $-1.01M | $2.48M | $3.98M | $3.64M | $4.98M | $2.75M | $3.78M | $1.32M | $2.11M | $19.00K | $682.78K | $-1.71M | $-1.11M |
| Accumulated Other Comprehensive Income Loss | $-742.91K | $-2.24M | $-846.01K | $-2.34M | $-833.84K | $-2.33M | $-803.86K | $-2.30M | $-405.79K | $-1.90M | $1.29M | $-57.74K | $717.64K | $-316.02K | $699.30K | $-89.23K | $98.10K | $-565.67K | $-262.73K | $-866.64K |
| Other Total Stockholders Equity | $24.46M | $24.46M | $24.24M | $24.24M | $23.26M | $23.26M | $23.26M | $23.26M | $23.26M | $23.26M | $10.86M | $10.86M | $10.86M | $10.86M | $10.60M | $10.60M | $10.49M | $10.49M | $9.80M | $10.41M |
| Total Stockholders Equity | $5.19M | $5.19M | $10.28M | $10.28M | $13.96M | $13.96M | $19.95M | $19.95M | $25.34M | $25.34M | $15.78M | $15.78M | $14.32M | $14.32M | $12.62M | $12.62M | $10.60M | $10.60M | $8.44M | $8.44M |
| Total Equity | $7.89M | $7.89M | $11.66M | $11.66M | $14.09M | $14.09M | $20.19M | $20.19M | $25.63M | $25.63M | $16.68M | $16.68M | $15.20M | $15.20M | $13.33M | $13.33M | $11.26M | $11.26M | $8.97M | $8.97M |
| Total Liabilities and Stockholders Equity | $51.07M | $51.07M | $51.44M | $51.44M | $56.55M | $56.55M | $57.68M | $57.68M | $57.18M | $57.23M | $67.51M | $67.51M | $75.97M | $75.97M | $68.79M | $68.79M | $62.93M | $62.93M | $43.37M | $43.37M |
| Minority Interest | $2.69M | $2.69M | $1.38M | $1.38M | $130.22K | $130.22K | $238.88K | $238.88K | $289.00K | $289.00K | $902.02K | $902.02K | $878.97K | $878.97K | $705.70K | $705.70K | $659.47K | $659.47K | $531.66K | $531.66K |
| Total Liabilities and Total Equity | $51.07M | $51.07M | $51.44M | $51.44M | $56.55M | $56.55M | $57.68M | $57.68M | $57.18M | $57.23M | $67.51M | $67.51M | $75.97M | $75.97M | $68.79M | $68.79M | $62.93M | $62.93M | $43.37M | $43.37M |
| Total Investments | $- | $- | $207.75K | $207.75K | $205.59K | $205.59K | $218.42K | $218.42K | $210.87K | $210.87K | $-535.88K | $- | $-1.50M | $- | $-841.65K | $- | $-1.50M | $- | $-672.91K | $- |
| Total Debt | $27.88M | $32.66M | $26.61M | $30.83M | $25.68M | $28.58M | $25.15M | $27.17M | $21.53M | $21.92M | $31.74M | $32.95M | $32.81M | $35.81M | $16.62M | $18.01M | $15.43M | $16.75M | $15.75M | $15.75M |
| Net Debt | $26.85M | $31.63M | $24.87M | $29.09M | $24.82M | $27.72M | $22.53M | $24.55M | $17.88M | $18.27M | $28.21M | $29.42M | $32.13M | $35.13M | $14.48M | $15.87M | $10.09M | $11.41M | $12.96M | $12.97M |
Annual Cash Flow
| Breakdown | September 30, 2024 | September 30, 2023 | September 30, 2022 | September 30, 2021 | September 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $-10.19M | $-11.01M | $112.23K | $3.30M | $2.83M |
| Depreciation and Amortization | $4.78M | $3.20M | $2.66M | $2.24M | $1.43M |
| Deferred Income Tax | $- | $616.76K | $106.78K | $208.83K | $-300.00K |
| Stock Based Compensation | $- | $- | $- | $- | $- |
| Change in Working Capital | $-302.41K | $4.46M | $7.43M | $-24.44M | $3.02M |
| Accounts Receivables | $1.37M | $252.31K | $18.37M | $-15.16M | $-6.71M |
| Inventory | $3.53M | $4.30M | $1.60M | $-559.72K | $-5.75M |
| Accounts Payables | $-4.18M | $260.02K | $-10.51M | $-6.78M | $11.54M |
| Other Working Capital | $-1.03M | $-353.55K | $-2.04M | $-1.93M | $3.94M |
| Other Non Cash Items | $767.51K | $140.52K | $-606.55K | $370.85K | $228.29K |
| Net Cash Provided by Operating Activities | $-4.94M | $-2.59M | $9.70M | $-17.66M | $7.72M |
| Investments in Property Plant and Equipment | $-2.42M | $-4.48M | $-8.18M | $-6.22M | $-5.18M |
| Acquisitions Net | $- | $- | $1.52M | $1.02M | $- |
| Purchases of Investments | $- | $- | $-210.87K | $- | $- |
| Sales Maturities of Investments | $- | $- | $-1.30M | $- | $- |
| Other Investing Activities | $1.03M | $-2.51M | $1.30M | $1.01M | $-1 |
| Net Cash Used for Investing Activities | $-1.39M | $-6.99M | $-6.88M | $-5.20M | $-5.18M |
| Debt Repayment | $1.83M | $5.35M | $-9.89M | $16.36M | $-159.24K |
| Common Stock Issued | $3.46M | $- | $12.41M | $- | $98.49K |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.45M | $2.37M | $9.91M | $2.21M | $271.21K |
| Net Cash Used Provided by Financing Activities | $6.75M | $7.72M | $11.79K | $18.56M | $210.46K |
| Effect of Forex Changes on Cash | $-229.67K | $-788.14K | $291.03K | $-379.13K | $133.20K |
| Net Change in Cash | $182.07K | $-2.65M | $3.12M | $-4.68M | $2.89M |
| Cash at End of Period | $1.34M | $1.16M | $3.81M | $684.34K | $5.36M |
| Cash at Beginning of Period | $1.16M | $3.81M | $684.34K | $5.36M | $2.47M |
| Operating Cash Flow | $-4.94M | $-2.59M | $9.70M | $-17.66M | $7.72M |
| Capital Expenditure | $-2.44M | $-7.50M | $-8.18M | $-6.22M | $-5.18M |
| Free Cash Flow | $-7.38M | $-10.09M | $1.52M | $-23.89M | $2.55M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-2.71M | $-2.71M | $-2.32M | $-2.32M | $-5.96M | $-2.98M | $-4.99M | $-2.49M | $-1.00M | $-500.46K | $1.20M | $599.95K | $1.67M | $834.39K | $1.43M | $715.08K | $1.79M | $894.70K | $924.71K | $462.35K |
| Depreciation and Amortization | $1.52M | $1.52M | $1.69M | $866.37K | $1.68M | $723.32K | $1.44M | $611.36K | $1.35M | $656.31K | $1.23M | $564.60K | $1.12M | $566.68K | $1.04M | $517.66K | $689.49K | $309.17K | $718.82K | $240.39K |
| Deferred Income Tax | $- | $- | $- | $- | $609.23K | $- | $7.53K | $- | $-30.52K | $- | $137.30K | $- | $168.47K | $- | $40.36K | $- | $-174.79K | $- | $-125.20K | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $-25.34K | $-25.34K | $2.01M | $2.01M | $903.83K | $784.98K | $3.56M | $1.78M | $1.98M | $3.69M | $5.45M | $6.56M | $-20.34M | $-7.10M | $-4.10M | $-1.10M | $3.86M | $-4.00M | $-847.98K | $-1.62M |
| Accounts Receivables | $79.73K | $79.73K | $825.38K | $825.38K | $-1.77M | $-1.08M | $1.37M | $883.04K | $8.02M | $4.01M | $10.46M | $5.18M | $-10.21M | $-5.06M | $-2.82M | $-2.52M | $-3.13M | $-1.20M | $-5.47M | $-2.15M |
| Inventory | $-105.95K | $-105.95K | $1.38M | $1.38M | $2.35M | $869.87K | $2.56M | $1.28M | $-746.59K | $-507.89K | $2.68M | $1.47M | $2.88M | $1.59M | $-2.06M | $-1.03M | $-8.11M | $-4.06M | $227.42K | $113.71K |
| Accounts Payables | $- | $- | $- | $- | $-192.96K | $- | $452.98K | $- | $-4.15M | $- | $-6.36M | $- | $-4.12M | $- | $-2.67M | $- | $8.14M | $- | $3.40M | $- |
| Other Working Capital | $876 | $876 | $-194.31K | $-194.31K | $521.72K | $997.61K | $-830.68K | $-387.75K | $-1.14M | $189.52K | $-1.33M | $-93.40K | $-8.89M | $-3.63M | $3.45M | $2.45M | $6.96M | $1.26M | $998.06K | $421.09K |
| Other Non Cash Items | $686.49K | $686.49K | $-5.27M | $-2.51M | $2.57M | $-111.51K | $-956.00K | $393.23K | $-1.03M | $-3.00M | $-4.32M | $-3.71M | $14.83M | $-2.41M | $9.78M | $-851.70K | $5.08M | $6.18M | $3.56M | $1.39M |
| Net Cash Provided by Operating Activities | $-524.56K | $-524.56K | $-3.89M | $-1.95M | $-3.17M | $-1.58M | $574.72K | $287.36K | $1.68M | $842.14K | $8.01M | $4.01M | $-16.23M | $-8.11M | $-1.44M | $-719.09K | $6.78M | $3.39M | $946.80K | $473.40K |
| Investments in Property Plant and Equipment | $-902.35K | $-902.35K | $-718.91K | $-307.82K | $-2.24M | $224.91K | $-5.26M | $-2.47M | $-6.74M | $-1.87M | $-1.44M | $-694.44K | $-1.86M | $-932.81K | $-4.36M | $-2.17M | $-4.20M | $-1.37M | $-981.15K | $-482.79K |
| Acquisitions Net | $- | $- | $- | $- | $143.70K | $- | $366.22K | $- | $1.52M | $- | $- | $- | $-161.18K | $- | $1.19M | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-210.87K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $850.50K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $338.34K | $338.34K | $587.22K | $176.13K | $-1.27M | $-1.27M | $20.10K | $20.10K | $-850.50K | $-850.50K | $-27.71K | $-27.71K | $-80.27K | $-80.27K | $586.98K | $586.98K | $-730.11K | $-730.11K | $-7.78K | $-7.78K |
| Net Cash Used for Investing Activities | $-564.01K | $-564.01K | $-131.69K | $-131.69K | $-2.10M | $-1.05M | $-4.89M | $-2.45M | $-5.43M | $-2.72M | $-1.44M | $-722.15K | $-2.03M | $-1.01M | $-3.17M | $-1.59M | $-4.20M | $-2.10M | $-981.15K | $-490.58K |
| Debt Repayment | $- | $- | $- | $- | $2.39M | $- | $2.96M | $- | $- | $- | $-1.87M | $- | $15.73M | $- | $623.79K | $- | $-339.21K | $- | $- | $- |
| Common Stock Issued | $- | $- | $2.26M | $- | $- | $- | $- | $- | $12.41M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $98.49K | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-98.49K | $-49.25K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $772.18K | $772.18K | $5.20M | $2.60M | $787.77K | $1.59M | $1.58M | $2.27M | $-8.62M | $1.90M | $-24.91K | $-1.89M | $1.47M | $8.60M | $54.37K | $678.16K | $403.70K | $15.25K | $278.46K | $139.23K |
| Net Cash Used Provided by Financing Activities | $772.18K | $772.18K | $5.20M | $2.60M | $3.17M | $1.59M | $4.55M | $2.27M | $3.79M | $1.90M | $-3.78M | $-1.89M | $17.21M | $8.60M | $1.36M | $678.16K | $-68.00K | $-34.00K | $278.46K | $139.23K |
| Effect of Forex Changes on Cash | $-39.23K | $-39.23K | $-75.61K | $-75.61K | $151.91K | $151.91K | $-545.98K | $-545.98K | $115.97K | $115.97K | $29.55K | $29.55K | $-207.52K | $-207.52K | $17.95K | $17.95K | $26.49K | $26.49K | $40.11K | $40.11K |
| Net Change in Cash | $- | $- | $893.29K | $446.64K | $-1.78M | $-892.39K | $-864.72K | $-432.36K | $274.78K | $137.39K | $2.85M | $1.42M | $-1.46M | $-729.74K | $-3.22M | $-1.61M | $2.57M | $1.28M | $284.22K | $162.16K |
| Cash at End of Period | $- | $- | $2.05M | $446.64K | $1.16M | $-892.39K | $2.94M | $-432.36K | $3.81M | $3.67M | $3.53M | $2.11M | $684.34K | $-729.74K | $2.14M | $3.75M | $5.36M | $4.08M | $2.79M | $162.16K |
| Cash at Beginning of Period | $- | $- | $1.16M | $- | $2.94M | $- | $3.81M | $- | $3.53M | $3.53M | $684.34K | $684.34K | $2.14M | $- | $5.36M | $5.36M | $2.79M | $2.79M | $2.51M | $- |
| Operating Cash Flow | $-524.56K | $-524.56K | $-1.95M | $-1.95M | $-3.17M | $-1.58M | $574.72K | $287.36K | $1.68M | $842.14K | $8.01M | $4.01M | $-16.23M | $-8.11M | $-1.44M | $-719.09K | $6.78M | $3.39M | $946.80K | $473.40K |
| Capital Expenditure | $-902.35K | $-902.35K | $-307.82K | $-307.82K | $-2.24M | $224.91K | $-5.26M | $-2.47M | $-6.74M | $-1.87M | $-1.44M | $-694.44K | $-1.86M | $-932.81K | $-4.36M | $-2.17M | $-4.20M | $-1.37M | $-981.15K | $-482.79K |
| Free Cash Flow | $-1.43M | $-1.43M | $-2.25M | $-2.25M | $-5.41M | $-1.36M | $-4.69M | $-2.18M | $-5.05M | $-1.02M | $6.57M | $3.31M | $-18.09M | $-9.05M | $-5.80M | $-2.89M | $2.58M | $2.02M | $-34.35K | $-9.39K |
Ostin Technology Group Co., Ltd. designs, develops, and manufactures thin-film transistor liquid crystal display (TFT-LCD) modules and polarizers in China. The company offers TFT-LCD solutions for drive IC, TCON board, and power supply applications; back light systems and special modules; LC display modules, touch panel modules, and smart display terminals; and polarizers used in the TFT-LCD display modules. It offers display modules to markets, such as consumer electronics, including AIOs, monitors, laptop computers, and tablets; automotive displays, including dashboard, and navigation and multimedia systems; and outdoor LCD displays, which are used to display multimedia graphics, such as company advertisements, promotions, scoreboards, and traffic signs. The company sells its products directly to customers, as well as to customers' designated system integrators. Ostin Technology Group Co., Ltd. was founded in 2010 and is based in Nanjing, China with manufacturing facilities in China.
$3.25
Stock Price
$118.69M
Market Cap
243
Employees
Nanjing, None
Location
Revenue (FY 2024)
$32.46M
-43.6% YoY
Net Income (FY 2024)
$-10.06M
8.1% YoY
EPS (FY 2024)
$-6.74
-764.1% YoY
Free Cash Flow (FY 2024)
$-7.38M
26.9% YoY
Profitability
Gross Margin
5.2%
Net Margin
-31.0%
ROE
-193.8%
ROA
-19.7%
Valuation
P/E Ratio
-0.56
P/S Ratio
0.17
EV/EBITDA
-7.73
Market Cap
$118.69M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-4.94M
-90.7% YoY
Free Cash Flow
$-7.38M
26.9% YoY
Balance Sheet Summary
Total Assets
$51.07M
-9.7% YoY
Total Debt
$27.88M
8.6% YoY
Shareholder Equity
$5.19M
-47.5% YoY
Dividend Overview
No Dividend Data
Ostin Technology Group Co., Ltd. doesn't currently pay dividends.
Ostin Technology Group Dividends
Explore Ostin Technology Group 's dividend history, including dividend yield, payout ratio, and historical payments.
Ostin Technology Group News
Read the latest news about Ostin Technology Group , including recent articles, headlines, and updates.
Ostin Technology Group Announces Pricing of $5.0 million Registered Direct Offering
Nanjing, China, April 15, 2025 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (“the Company”) (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced that it has entered into a securities purchase agreement with several investors for the purchase and sale of (i) 9,090,908 Class A ordinary shares (the “Class A Ordinary Shares”), par value $0.001 per share, of the Company; and (ii) Class A Ordinary Share purchase warrants to purchase up to 90,909,080 Class A Ordinary Shares (the “Warrants”); and (iii) up to 90,909,080 Class A Ordinary Shares issuable upon exercise of the Warrants. Each Class A Ordinary Share is being sold together with two associated Warrants, each to purchase one Class A Ordinary Share at a combined offering price of $0.55 per Class A Ordinary Share and associated Warrants.
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced positive data in the prevention or delay of amputation during the treatment of primary osteosarcoma for OST-HER2 combined palliative radiation in dogs with unresected appendicular osteosarcoma. The treatment led to clinical and radiographic arrest of the primary tumor and prolonged time to metastasis.
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has submitted a request for a formal meeting with the Center for Biologics Evaluation and Research (CBER) of the United States Food & Drug Administration (FDA) to gain alignment on the clinical endpoints required to support Breakthrough Therapy Designation (BTD) and Accelerated Approval v.
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria monocytogenes (Lm) immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma. “We are making rapid progress in putting together an appropriate data package to achieve accelerated.
OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for.
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company's Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma.
OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting (SAM) in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway (ILAP) with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for OST-HER2, its immunotherapy candidate for the prevention of recu.
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) that a patent will be issued covering the manufacturing methods required for the OST-HER2 commercial product. The USPTO granted a Patent Term Adjustment of 572 days, providing market exclusivity for the OS.
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the commercial manufacture of OST-HER2. The Company is currently organizing additional data in relation to the recently-completed treatment phase of its Phase 2b trial of OST-HER2 in the prevention of recurrence of lung metastatic osteosarcoma in preparation for a.
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company's HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res.
Ostin Technology Group Announces Update to Effective Date of Reverse Share Split
Nanjing, China, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced an update to the effective date of its previously approved reverse share split of the Company's Class A ordinary shares, with the split ratio set at 1-for-10 (the “Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2024. The effective date for the Reverse Share Split has been revised from December 26, 2024 to December 31, 2024 and the Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on December 31, 2024, under the existing ticker symbol “OST.” The new CUSIP number for the Company's Class A ordinary shares will be G67927114.
Ostin Technology Group Announces Effective Date of Reverse Share Split
Nanjing, China, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-10 (the “The Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2024. The Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on December 26, 2024, under the existing ticker symbol “OST.” The new CUSIP number for the Company's Class A ordinary shares will be G67927114.
Ostin Technology Group Announces Results of Extraordinary General Meeting
Nanjing, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, announced the results of an Extraordinary General Meeting held on November 26, 2024, at 10:00 a.m. Beiijng Time (November 25, 2024, at 9:00 p.m., U.S. Eastern time) at its executive office at Floor 1, Building F4, 1 Zidong Road, Qixia District, Nanjing, Jiangsu Province, China.
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
NEW YORK--(BUSINESS WIRE)--OS Therapies Incorporated (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dose. This last patient is expected to complete its final radiological imaging evaluation as part of the 12-month Ev.
Ostin Technology Group Unveils Strategic Expansion into North American Market With its US Subsidiary Begins Operation
Nanjing, China, April 10, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, announces that Pintura.Life LLC, the Company's wholly owned subsidiary in the United States (“Pintura.Life”), has officially commenced its operation.
Ostin Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Nanjing, China, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that the Company had received a written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2024, indicating that for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Nasdaq notification letter has no current effect on the listing or trading of the Company's securities on the Nasdaq Capital Market, which will continue to trade uninterrupted on Nasdaq under the ticker "OST".
Ostin Technology Group Announces Major Product Upgrade to Pintura Photo Sharing Product
Nanjing, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announces new upgrade to its photo sharing product, Pintura. The new upgrades will elevate user experience with improvements to both Pintura's hardware and software system. The Company plans to launch the upgraded Pintura product at the next Consumer Electronics Show (CES) in early 2024, which is also expected to be available for purchase through short-video platforms.
Ostin Technology Group Co. Secured New Purchase Orders of Treadmill Screen Products; Officially Opens Douyin Store with Latest Smartwatch Products Now Available for Purchase
Nanjing, China, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced it has secured new purchase orders of nearly 5,000 “21.5-inch module” treadmill screen products from a leading fitness equipment manufacturer in China. The Company also unveiled the grand opening of its flagship Douyin store. This exciting launch unveils the M4 and GT8-PRO smartwatches, now available for purchase online.
Ostin Technology Group Co., Ltd. to Hold Annual General Meeting of Shareholders on September 28, 2023
Nanjing, China, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the “Company”) (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that it expects to hold its 2023 annual general meeting of shareholders on September 28, 2023 at 8:00 p.m., Beijing Time (September 28, 2023, at 8:00 a.m., Eastern Time), at its executive office at Building 2, 101/201, 1 Kechuang Road, Qixia District, Nanjing, Jiangsu Province, China 210046.
Ostin Technology Group Plans to Launch New M4 and GT8-PRO Smartwatches Via Short-Video Platforms
Nanjing, China, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced the Company plans to launch its new smartwatch products, M4 and GT8-PRO, through one of the most popular Chinese short-video platforms. These smartwatch products are expected to be officially available for purchase on Douyin (TikTok) platform in the third quarter this year. The Company is also expected to market and sell its smartwatch products through other popular short-video platforms, including Kuaishou (Kwai) and WeChat Channel.
Ostin Technology Group Secures Orders for Metro Projects in Beijing, Tianjin, and Nanjing of China
Nanjing, China, July 17, 2023 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. (the "Company") (Nasdaq: OST), a supplier of display modules and polarizers in China, today announced that it has secured orders to purchase platform door displays, metro Passenger Information System (“PIS”) screens, and metro platform monitors, which are expected to be used for metro projects in Beijing, Tianjin, and Nanjing of China.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for OST.